Free Trial
NASDAQ:VTVT

vTv Therapeutics (VTVT) Stock Price, News & Analysis

vTv Therapeutics logo
$14.26 -0.36 (-2.43%)
Closing price 08/7/2025 03:59 PM Eastern
Extended Trading
$14.52 +0.25 (+1.79%)
As of 08/7/2025 04:10 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About vTv Therapeutics Stock (NASDAQ:VTVT)

Key Stats

Today's Range
$14.10
$14.48
50-Day Range
$13.53
$17.50
52-Week Range
$12.58
$26.99
Volume
642 shs
Average Volume
2,210 shs
Market Capitalization
$45.51 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$35.50
Consensus Rating
Buy

Company Overview

vTv Therapeutics Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
38th Percentile Overall Score

VTVT MarketRank™: 

vTv Therapeutics scored higher than 38% of companies evaluated by MarketBeat, and ranked 706th out of 921 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    vTv Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    vTv Therapeutics has received no research coverage in the past 90 days.

  • Read more about vTv Therapeutics' stock forecast and price target.
  • Price to Earnings Ratio vs. the Market

    The P/E ratio of vTv Therapeutics is -4.74, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of vTv Therapeutics is -4.74, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    vTv Therapeutics has a P/B Ratio of 3.18. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

  • Read more about vTv Therapeutics' valuation and earnings.
  • Percentage of Shares Shorted

    0.98% of the float of vTv Therapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    vTv Therapeutics has a short interest ratio ("days to cover") of 2.1, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in vTv Therapeutics has recently decreased by 99.10%, indicating that investor sentiment is improving significantly.
  • Dividend Yield

    vTv Therapeutics does not currently pay a dividend.

  • Dividend Growth

    vTv Therapeutics does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    0.98% of the float of vTv Therapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    vTv Therapeutics has a short interest ratio ("days to cover") of 2.1, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in vTv Therapeutics has recently decreased by 99.10%, indicating that investor sentiment is improving significantly.
  • News Coverage This Week

    MarketBeat has tracked 2 news articles for vTv Therapeutics this week, compared to 1 article on an average week.
  • MarketBeat Follows

    3 people have added vTv Therapeutics to their MarketBeat watchlist in the last 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, vTv Therapeutics insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    Only 4.20% of the stock of vTv Therapeutics is held by insiders.

  • Percentage Held by Institutions

    Only 17.51% of the stock of vTv Therapeutics is held by institutions.

  • Read more about vTv Therapeutics' insider trading history.
Receive VTVT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for vTv Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

VTVT Stock News Headlines

Is Elon's empire crumbling?
The Tesla Shock Nobody Sees Coming While headlines scream "Tesla is doomed"... Jeff Brown has uncovered a revolutionary AI breakthrough buried inside Tesla's labs. One that is helping AI escape from our computer screens and manifest itself here in the real world all while creating a 25,000% growth market explosion starting as early as October 23rd.
See More Headlines

VTVT Stock Analysis - Frequently Asked Questions

vTv Therapeutics' stock was trading at $13.81 at the beginning of 2025. Since then, VTVT stock has increased by 3.3% and is now trading at $14.2650.

vTv Therapeutics Inc. (NASDAQ:VTVT) announced its quarterly earnings results on Thursday, May, 15th. The biotechnology company reported ($0.77) earnings per share for the quarter, missing analysts' consensus estimates of ($0.73) by $0.04.

vTv Therapeutics shares reverse split on Tuesday, November 21st 2023.The 1-40 reverse split was announced on Tuesday, November 21st 2023. The number of shares owned by shareholders was adjusted after the market closes on Tuesday, November 21st 2023. An investor that had 100 shares of stock prior to the reverse split would have 3 shares after the split.

vTv Therapeutics (VTVT) raised $125 million in an initial public offering (IPO) on Thursday, July 30th 2015. The company issued 7,800,000 shares at $15.00-$17.00 per share. Piper Jaffray and Stifel acted as the underwriters for the IPO and Canaccord Genuity and Janney Montgomery Scott were co-managers.

Shares of VTVT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that vTv Therapeutics investors own include OPKO Health (OPK), Sorrento Therapeutics (SRNE), NVIDIA (NVDA), NIO (NIO), VBI Vaccines (VBIV), Vaxart (VXRT) and Advanced Micro Devices (AMD).

Company Calendar

Last Earnings
5/15/2025
Today
8/07/2025
Next Earnings (Estimated)
8/14/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MED - BIOMED/GENE
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:VTVT
CIK
1641489
Employees
9
Year Founded
N/A

Price Target and Rating

High Price Target
$36.00
Low Price Target
$35.00
Potential Upside/Downside
+148.9%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
2 Analysts

Profitability

EPS (Trailing Twelve Months)
($3.01)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$18.46 million
Net Margins
N/A
Pretax Margin
-134,723.52%
Return on Equity
-121.46%
Return on Assets
-46.75%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
7.39
Quick Ratio
7.39

Sales & Book Value

Annual Sales
$17 thousand
Price / Sales
2,680.98
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$4.48 per share
Price / Book
3.18

Miscellaneous

Outstanding Shares
3,195,000
Free Float
3,061,000
Market Cap
$45.58 million
Optionable
Not Optionable
Beta
0.57

Social Links

10 Stocks Set to Soar in Fall 2025 Cover

Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Fall 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.

Get This Free Report

This page (NASDAQ:VTVT) was last updated on 8/8/2025 by MarketBeat.com Staff
From Our Partners